Trial Search Results

A Study of Nilotinib Versus Imatinib in GIST Patients

This study will evaluate efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Novartis Pharmaceuticals

Stanford Investigator(s):


  • Drug: Nilotinib (AMN107)
  • Drug: imatinib (STI571)


Phase 3


Inclusion Criteria:

   1. Histologically confirmed diagnosis of GIST which is unresectable and/or metastatic and

      - have not received any prior anti-neoplastic therapy other than adjuvant imatinib.
      Note: newly diagnosed patients may have received up to 14 days of treatment with
      imatinib for disease management while awaiting entry to the study or

      - recurrent GIST after stopping adjuvant treatment with imatinib and no subsequent
      treatment with any other therapies.

   2. At least one measurable site of disease on CT/MRI scan

   3. Performance status ≤ 2 (capable of self-care but unable to carry out any work)

   4. Normal organ, electrolyte and marrow function

Exclusion Criteria:

   1. Any prior anti-neoplastic therapy with the exception of patients who have received
   adjuvant imatinib or patients with newly diagnosed metastatic/ unresectable GIST whose
   disease requires therapy while awaiting entry to the study.

   2. Disease progression during adjuvant therapy with imatinib

   3. History of active malignancy (other than GIST) within 10 years prior to study entry
   with the exception of previous or concomitant basal cell skin cancer, previous
   cervical carcinoma in situ.

   4. Impaired cardiac function

Other protocol-defined inclusion/exclusion criteria may apply

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting